CD276 and neoplasm: NCT03729596 (Phase 1, completed) and NCT05555117 (Phase 2, active) are being used to investigate humanized mAb vobramitamab loaded with duocarmazine targeting B7-H3, and the preliminary results showed a tolerable safety profile with a decrease in tumor lesion size in mCRPC patients.